ZYME vs MGNX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 03, 2026

ZYME

60.3
AI Score
VS
ZYME Wins

MGNX

55.1
AI Score

Investment Advisor Scores

ZYME

60score
Recommendation
HOLD

MGNX

55score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric ZYME MGNX Winner
Forward P/E 20.8333 60.9756 ZYME
PEG Ratio 0 0.01 Tie
Revenue Growth -90.6% 378.0% MGNX
Earnings Growth 0.0% -70.4% ZYME
Tradestie Score 60.3/100 55.1/100 ZYME
Profit Margin 0.0% -8.3% ZYME
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

ZYME 1M: -19.0% · 3M: -0.7% MGNX 1M: -17.1% · 3M: -21.7%

Current Technical Phase

ZYME

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 40

RSI (14): 40.2 · Price: $25.15

MGNX

Markdown
Sell / avoid

Price below a falling SMA50 (slope -4.9%), weak momentum, RSI 38

RSI (14): 38.2 · Price: $3.58

Fundamentals Snapshot

Metric ZYME MGNX
Market Cap — —
Forward P/E 28.9 -2.4
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.9% 3.8%
Gross Margin -2.5% 0.0%
Operating Margin -9.2% -0.4%
EPS -2.02 -1.48
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, ZYME is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.